XML 18 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (3,505) $ (9,214)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation and amortization of property, plant and equipment 1,223 1,041
Amortization of intangible assets 176 272
Deferred income taxes (84)
Amortization of debt issuance costs and discount 466 812
Debt extinguishment 884
Loss on write down of assets and note receivable 393 111
Loss on sale and disposal of assets   215
Stock-based compensation 1,950 2,265
Changes in assets and liabilities:    
Accounts receivable (202) 296
Inventories (275) (946)
Prepaid expenses and other current assets (400) 45
Accounts payable and accrued expenses 2,153 497
Accrued payroll and related liabilities 518 (348)
Deferred revenue and customer deposits 69 (83)
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES 723 (8,509)
CASH FLOWS FROM INVESTING ACTIVITIES    
Repayment of note receivable 4
Proceeds on sale and disposal of assets 110
Investment in patent and trademark assets (283) (184)
Purchase of Klarity license (50)
Purchases of property, plant and equipment (1,068) (588)
NET CASH USED IN INVESTING ACTIVITIES (1,347) (712)
CASH FLOWS FROM FINANCING ACTIVITIES    
Payments on capital lease obligations (512) (464)
Net proceeds from public equity offering 2,940
Payments on Park deferred acquisition obligation (53) (101)
Proceeds from SWK debt, net of costs 15,518
Principal payments on LSAF note payable (13,999)
Net proceeds from ATM sales of common stock 642 162
Net proceeds from exercise of warrants and stock options, net of taxes remitted for RSU’s 2,643 179
NET CASH PROVIDED BY FINANCING ACTIVITIES 2,720 4,235
NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH 2,096 (4,986)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period 4,219 9,053
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period 6,315 4,067
RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD:    
Cash and cash equivalents 6,115 3,867
Restricted cash 200 200
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD 6,315 4,067
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:    
Cash paid for income taxes 4 9
Cash paid for interest 1,006 1,045
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Issuance of stock options for consulting services included in accounts payable and accrued expenses 108
Final fee on note payable recorded as debt discount and Included in accrued expenses 800
Estimated relative fair value of warrants issued in connection with note payable 982
Note receivable in connection with sale of assets 410
Eton Pharmaceuticals [Member]    
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Gain on deconsolidation (5,725)
Investment loss 3,247 1,453
Surface Pharmaceuticals [Member]    
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Gain on deconsolidation (5,320)
Investment loss $ 230